Vedana Therapeutics Launches With $46M to Target PACAP Neuropeptide for Migraine
Executive Summary
Vedana Therapeutics launched from stealth on June 17, 2026 with a $46 million Series A round to develop antibody drugs targeting PACAP (pituitary adenylate cyclase-activating polypeptide), a neuropeptide that drives migraine attacks through a pathway distinct from the well-established CGRP mechanism. The startup, backed by Westlake BioPartners and Canaan Partners, is led by the scientific and clinical teams that built the multi-billion-dollar CGRP migraine drug class at Alder Biopharmaceuticals, Labrys Biologics, and Amgen. With two programs — one targeting PACAP alone and a dual PACAP/CGRP bispecific — Vedana aims to enter human trials in 2027.
Context / Background
The CGRP inhibitor class — including Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) — transformed migraine prevention when it launched in 2018. These monoclonal antibodies block calcitonin gene-related peptide, a neuropeptide central to migraine pathophysiology. Combined, the class generates over $7 billion in annual revenue.
But a persistent problem remains: more than 50% of patients either do not respond to CGRP therapies or discontinue them within the first year. This treatment gap — estimated at 15–20 million patients worldwide — has sparked a race to identify the next migraine target. PACAP, a 38-amino-acid neuropeptide, has emerged as the leading candidate. It triggers vasodilation and neuroinflammation through PAC1, VPAC1, and VPAC2 receptors — a signaling cascade parallel to, but distinct from, CGRP.
The Data / The Deal
| Metric | Detail |
|---|---|
| Company | Vedana Therapeutics (stealth until June 17, 2026) |
| Funding | $46 million Series A |
| Lead Investors | Westlake BioPartners, Canaan Partners |
| Target | PACAP neuropeptide (anti-PACAP monoclonal antibodies) |
| Pipeline | 2 programs: anti-PACAP monotherapy + PACAP/CGRP bispecific |
| Clinical Timeline | Human trials expected to start in 2027 |
| Key Competitor | Lundbeck (ALD1910, Phase 2, via $2B Alder acquisition) |
| Other Competitors | Mentari Therapeutics (reverse merger), Slate Medicines ($130M raised) |
| Leadership | CEO Anurag Agarwal; CSO Leon Garcia (ex-Alder PACAP lead); CMO Ernesto Aycardi (ex-Teva Ajovy lead) |
| Board | Rob Lenz (ex-Amgen Aimovig head), Marcelo Bigal (ex-Labrys CMO) |
Expert Insight
Anti-pattern: Assuming PACAP will just be “CGRP 2.0.” Experienced teams know that the PACAP pathway has significant safety baggage. PACAP is broadly expressed — in the pituitary, adrenal medulla, and autonomic nervous system. Lundbeck’s ALD1910 showed signals of liver enzyme elevation and blood pressure effects in Phase 2, which is why the program hasn’t accelerated faster despite positive efficacy data. The winner in this space won’t be the company with the best PACAP binder — it will be the one that solves the therapeutic window problem. Vedana’s dual-targeting bispecific may help by allowing lower doses of each component.
Another underappreciated dimension: CGRP drugs succeeded partly because neurologists were desperate for migraine-specific options after decades of repurposed antidepressants and beta-blockers. PACAP drugs face a higher bar — they must demonstrate superiority over established, well-reimbursed CGRP therapies, not just novelty. Trial design matters enormously here; a head-to-head against CGRP standard-of-care is expensive but may be the only path to commercial relevance.
Frequently Asked Questions
What is PACAP and why does it matter for migraines?
PACAP (pituitary adenylate cyclase-activating polypeptide) is a 38-amino-acid neuropeptide that acts as a potent vasodilator and neuroinflammatory mediator. In migraine patients, PACAP levels spike during attacks, and intravenous PACAP infusion reliably triggers migraine-like headaches in clinical studies. Unlike CGRP, which primarily signals through the CGRP receptor, PACAP activates three distinct receptors (PAC1, VPAC1, VPAC2), offering multiple therapeutic intervention points that may benefit patients who don’t respond to CGRP blockade alone.
How does Vedana’s approach differ from Lundbeck’s anti-PACAP program?
Lundbeck acquired the anti-PACAP antibody ALD1910 through its $2 billion purchase of Alder Biopharmaceuticals in 2019. ALD1910 targets the PACAP ligand directly (like CGRP antibodies bind CGRP itself). Vedana has not disclosed whether its antibodies target the ligand or the PAC1 receptor, but its bispecific program — simultaneously targeting PACAP and CGRP — is a differentiated approach. The hypothesis: dual blockade may deliver superior efficacy for the hardest-to-treat patients, though it also introduces more complex safety considerations.
Is the anti-PACAP approach validated by clinical data?
Partially. Lundbeck’s ALD1910 succeeded in multiple Phase 2 trials, demonstrating statistically significant reductions in monthly migraine days. However, the magnitude of benefit has been modest relative to CGRP antibodies, and safety signals (transaminase elevations, blood pressure changes) have prevented an accelerated push to Phase 3. The field consensus: PACAP is a validated target, but the optimal modality (ligand blockade vs. receptor antagonism), dosing schedule, and patient selection criteria remain open questions — exactly the kind of problem a well-funded, focused startup is positioned to solve.
Further Reading
- GLP-1 Peptide Therapeutics: The Complete 2026 Landscape
- Peptide Drug Conjugates in the Clinic: 2026 Pipeline Review
- Neuropeptide Therapeutics Beyond CGRP: Emerging Targets and Strategies
Last reviewed: June 2026. Peptide Proof Editorial Team. Source: BioPharma Dive
